Reimbursed Care Access in Chile

Currently classified as a strictly controlled substance under Chile's national drug law (Ley N°20.000), with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine nasal spray (Spravato) holds a registered sanitary record for Chile (commercial registration entry available in Chilean pharmaceutical registries), and is marketed by Janssen for treatment‑resistant depression under strict medical supervision; its availability is clinic‑based and delivered under controlled outpatient protocols rather than broad public outpatient reimbursement. The product registration (Spravato) is listed in Chilean pharmaceutical equivalence/regulatory aggregators (Registro sanitario: F-26406/21 noted). #

Regulatory and payer context: Spravato's registered status means it may be legally imported/distributed and prescribed by psychiatrists in Chile, but reimbursement through the public insurer (FONASA) or private ISAPRE plans is not automatic. In practice, access is typically delivered via private psychiatric clinics or centers that provide the supervised intranasal dosing protocol and associated psychotherapy; coverage decisions depend on individual ISAPRE policies or out‑of‑pocket payment, and there is no broad national program that guarantees routine public reimbursement for Spravato as of the latest public product registration information. #

Clinical indications and oversight: The product is used in the specific indication of treatment‑resistant depression (TRD) in combination with an oral antidepressant and requires administration under clinician supervision with monitoring per the product's safety profile; prescribing and administration must follow the manufacturer’s protocol and local medical guidelines applicable to high‑risk psychotropic medications.

Ketamine is an approved and registered anesthetic/analgesic in Chile and is used routinely in hospitals for anesthesia and pain management; in recent years it has also been adopted in outpatient/private psychiatric practice as an off‑label intervention for treatment‑resistant depression and other refractory conditions. Media coverage and professional commentary in Chile document both clinical use and intermittent supply/stock issues for ketamine in public hospitals, confirming its role in standard medical practice and emergent psychiatric protocols. #; #; #

Clinical delivery and reimbursement nuance: In Chile ketamine for psychiatric indications is generally delivered in private specialist clinics and IN‑clinic protocols (intravenous, intramuscular, sublingual or intranasal) under psychiatrist/anesthetist supervision. Several Chilean clinics and institutes explicitly advertise ketamine‑assisted therapy programs (describing evaluation, multi‑session protocols, and integration psychotherapy), which indicates a private‑sector delivery model; routine public (FONASA) coverage for ketamine when used for off‑label psychiatric indications is not standardized and is typically handled on a case‑by‑case or private payment basis. Examples of local clinical providers and informational pages documenting private‑sector ketamine therapy activity include ketaminachile.cl and private psychiatric institutes offering protocols. #; #

Regional/state nuances: Chile’s health system is nationally organized (FONASA public, ISAPRE private insurers) rather than state‑by‑state; therefore regional differences in access are driven by local provider presence and supply chain factors (for example recent hospital stock shortages were reported in major Santiago hospitals and other regional centers). Public hospital formularies historically include ketamine for anesthetic/analgesic indications, but psychiatric off‑label programs have predominantly arisen in private settings.

Currently classified as a strictly controlled substance under national drug scheduling laws (Ley N°20.000), with no authorized medical use outside approved clinical research; as the primary psychoactive of ayahuasca, its presence gives legal risks to unregulated ayahuasca use. #; (note: legal practice around plant brews can be complex but the active alkaloid DMT remains controlled).

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (There are anecdotal/private‑sector retreat claims internationally, but in Chile there is no recognized medical framework or public reimbursement for ibogaine therapy.) #

While plant preparations themselves occupy a gray area in some jurisdictions, the active compound DMT is controlled in Chile; therefore ayahuasca has no authorized medical/reimbursement pathway outside approved research or any narrow religious exemptions, and its use carries legal risk absent explicit authorization. #; #

Currently classified as a strictly controlled substance under national drug scheduling laws; mescaline (and preparations/ extracts intended for ingestion) have no authorized medical use or public reimbursement outside approved clinical research. The legal treatment of mescaline-containing cacti (ornamental vs. prepared for ingestion) may be distinct in practice, but the active alkaloid is controlled. #; #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Synthetic phenethylamines in the 2C family are treated as illicit/scheduled compounds under Chilean narcotics law.) #